💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sildenafil

CHEMBL192 Phase 4 已批准 Small molecule
Half-Life
4 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
474.6 g/mol
LogP
1.5
Phase
4

Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow. It is used both to treat erectile dysfunction and, at different doses, to lower abnormally high blood pressure in the arteries of the lungs (pulmonary arterial hypertension).

分子量

474.5800 g/mol

LogP

1.50

TPSA

118.00 Ų

Lipinski 五规则

符合

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Benign Prostatic Hyperplasia Glaucoma Age-Related Macular Degeneration Respiratory Disease Non-Small Cell Lung Cancer Osteoporosis Chronic Obstructive Pulmonary Disease Parkinson's Disease Migraine Schizophrenia Systemic Lupus Erythematosus Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer HIV/AIDS Hepatitis C Heart Failure Cardiovascular Disease Prostate Cancer Colorectal Cancer

药物分类

G — G - Genito-Urinary System and Sex Hormones

作用机制

Selective PDE5 inhibitor increasing cGMP.

Pharmacokinetics (PK)

Half-Life 4 hours

Pharmacodynamics (PD)

机制

Selective PDE5 inhibitor increasing cGMP.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12

                

                

                
                

                    
InChI

                    
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H30N6O4S

                    

                    
                    

                        
HBD / HBA

                        
1 / 8

                    

                    
                    

                        
可旋转键数

                        
7

                    

                    
                    
                    

                        
重原子数

                        
33

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PDE5A (Phosphodiesterase 5)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP3A4 (Cytochrome P450 3A4)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Sildenafil + Tamsulosin
                            
                        

                        
                        
Combining tamsulosin (alpha-1 blocker) with sildenafil (PDE-5 inhibitor) produces additive vasodilation, substantially increasing the risk of symptomatic hypotension, dizziness, and syncope.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Sildenafil + Nitroglycerin
                            
                        

                        
                        
Combining sildenafil with nitrates causes profound, potentially fatal hypotension; this combination is absolutely contraindicated.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow. It is used both to treat erectile dysfunction and, at different doses, to lower abnormally high blood pressure in the arteries of the lungs (pulmonary arterial hypertension).

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective PDE5 inhibitor increasing cGMP.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Sildenafil: Half-life: 4 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Sildenafil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Tamsulosin
                            Small molecule
                        
                        
                        
                            Finasteride
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL192.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135398744.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.